The Cytoreductive Effect of Radiotherapy for Small Cell Ovarian Carcinoma of the Pulmonary Type: A Case Report and Review of the Literature

Table 1

A review of the literature: the characteristics, the treatment, and the outcome of small cell ovarian carcinoma, pulmonary type.

Author	Year	Age	Stage	Operation	Postoperative treatment	Outcome
Eichhorn et al. [1]	1992	62	1a	RSO	None	DOD, 4 Mo
		59	1a	TAH, RSO	Unknown	Unknown
		55	1a	TAH, BSO	Unknown	Unknown
		28	1c	TAH, BSO, OMT, appendectomy, peritoneal biopsies	Unknown	AWD, 6 Mo
		85	2b	BSO	None	DOD, 1 Mo
		76	3b	BSO (subtotal resection)	Unknown	DOD, 12 Mo
		50	3b	LSO	Unknown	Unknown
		72	3b	TAH, BSO, OMT	CDDP, CPM	DOD, 12 Mo
		64	3b	TAH, BSO, OMT, LND, colectomy, appendectomy	CDDP, CPM, ADR	AWD, 8 Mo
		49	3b	LSO, ileocolectomy, right para-aortic LND	CDDP, CPM, ADR, MTX, 5-FU	DOD, 13 Mo
		46	3c	TAH, BSO, retroperitoneal LND	CDDP, CPM, ADR, VP-16, VCR	ANED, 7.5 years
Chang et al. [2]	1992	22	1a	LSO, enucleation of the right ovarian tumor	CDDP, CPM, ADR	ANED, 84 Mo
Fukunaga et al. [3]	1997	64	1a	TAH, BSO, OMT, pelvic and para-aortic LND	CDDP, CPM	DOD, 10 Mo
Lim et al. [4]	1998	28	4b	TAH, BSO	CDDP, VP-16, BLM	ANED, 34 Mo
Mebis et al. [5]	2004	54	3c	TAH, BSO, OMT	CDDP, IFM, VP-16	DOD, 14 Mo
Rund and Fischer [6]	2006	56	3c	TAH, BSO, OMT, pelvic LND, splenectomy, segmental resection of ileum and sigmoid colon	CDDP, VP-16	AWD, 7 Mo
	2006	39	3a	TAH, BSO, OMT	CDDP, VP-16, PTX	DOD, 16 Mo
Grandjean et al. [7]	2007	32	1a	BSO, OMT, left pelvic LND	CDDP, VP-16	ANED
Saitoh-Sekiguchi et al. [8]	2007	55	3c	TAH, BSO, OMT, cytoreductive surgery of dissemination	CDDP, CPT-11	ANED, 12 Mo
Suzuki et al. [9]	2007	49	1c(a)	TAH, BSO, pelvic and para-aortic LND, OMT	CBDCA, PTX	ANED, 36 Mo
Reckova et al. [10]	2010	67	4b	TAH, BSO, OMT, appendectomy	CBDCA, VP-16	DOD, 24 Mo
Ikota et al. [11]	2012	68	1a	TAH, BSO, OMT	None	ANED, 10 Mo
Kira et al. [12]	2012	33	3c	TAH, BSO, OMT, pelvic and para-aortic LND	CDDP, CPT-11	DOD, 6 Mo
Tsolakidis et al. [13]	2012	55	3c	TAH, BSO, OMT, sigmoidectomy, pelvic and para-aortic LND	CBDCA, VP-16	AEND, 21 Mo
Kurasaki et al. [14]	2013	54	3a	TAH, BSO, OMT	CBDCA, PTX	ANED, 22 Mo
Rubio et al. [15]	2015	37	3b	TAH, BSO, OMT, pelvic LND	CDDP, VP-16	DOD, 4 Mo

TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; LND, lymph node dissection; OMT, omentectomy; CDDP, cisplatin; CBDCA, carboplatin; PTX, paclitaxel; ADR, doxorubicin; CPM, cyclophosphamide; VP-16, etoposide; CPT-11, irinotecan; IFM, ifosfamide; BLM, bleomycin; VCR, vincristine; MTX, methotrexate; 5-FU, 5-fluorouracil; DOD, dead of disease; ANED, alive with no evidence of disease; AWD, alive with recurrent or residual disease; Mo, months.